Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?

Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?

Abstract Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the “exhausted” immune system and increasing the number of T cells active against pathogens losing tolerogenic s...

Full description

Bibliographic Details
Main Authors: Cecilia Azzarà, Andrea Lombardi, Andrea Gramegna, Margherita Ori, Andrea Gori, Francesco Blasi, Alessandra Bandera
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Infectious Diseases
Subjects:
Immune checkpoint inhibitors
Non-tuberculous mycobacteria
Immune-related adverse events
Mycobacterium chimaera
NTM-LD
Online Access:https://doi.org/10.1186/s12879-023-08537-w

Internet

https://doi.org/10.1186/s12879-023-08537-w

Similar Items